Roux, S. http://orcid.org/0000-0002-7427-9361
Gaboury, I.
Gionet-Landry, N.
Garant, M.-P.
Beaulieu, M.-C.
Carrier, N.
Cabana, F.
Boire, G.
Funding for this research was provided by:
Eli Lilly Canada (B3D-CA-O037)
Amgen Canada (92764-JT)
Merck & Co. Inc (ISS51992)
Novartis Pharma Canada Inc. (N/A)
The Alliance for Better Bone Health (N/A)
Servier Canada Inc (N/A)
Warner Chilcott Canada (N/A)
Article History
Received: 8 August 2017
Accepted: 27 December 2017
First Online: 14 February 2018
Compliance with ethical standards
:
: ᅟ
: No disclosure except GB who has received lecture fees or advisory board fees from BMS Canada, Celgene Canada, Novartis Canada, and UCB Canada; GB and SR from Eli Lilly Canada, Amgen Canada, and Pfizer Canada; IG has received research funding from Merck Canada, and SR from BMS and Pfizer Canada.
: All procedures were in accordance with the ethical standards of the CHUS institutional research committee and with TCPS 2 (2014)- the latest edition of Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.